Medication Monitor

SORT BY:      Most Recent      Most Viewed     
List-View      Table-View
Generic Name (Trade Name—Company)
  • April 10, 2019

    FDA approved romosozumab-aqqg to treat osteoporosis in postmenopausal women at high risk of fracture. Women at high risk have a history of osteoporotic fracture or multiple risk factors for fracture, or have experienced treatment failure or intolerance to other osteoporosis therapies.

    Romosozumab-aqqg is a monoclonal antibody that blocks the effects of the protein sclerostin and works mainly by increasing new bone formation. One dose consists of two injections, one immediately following the other, given once a month by a health professional. The bone-forming effect wanes after 12 doses, so more than 12 doses should not be used. If osteoporosis therapy is needed after the 12 doses, patients should begin an osteoporosis treatment that reduces bone breakdown.

    Safety and efficacy of the agent were demonstrated in two clinical trials involving a total of more than 11,000 women with postmenopausal osteoporosis. In the first trial, one year of treatment with romosozumab-aqqg lowered the risk of a new vertebral fracture by 73% compared with placebo. This benefit was maintained over the second year of the trial, when the agent was followed by 1 year of denosumab (another osteoporosis therapy) compared with placebo followed by denosumab.

    In the second trial, one year of treatment followed by 1 year of alendronate (another osteoporosis therapy) reduced the risk of a new vertebral fracture by 50% compared with 2 years of alendronate alone. Romosozumab-aqqg followed by alendronate also reduced the risk of fractures in nonvertebral fractures compared with alendronate alone.

    The agent increased the risk of cardiovascular death, heart attack, and stroke in the alendronate trial but not in the placebo trial. Therefore, romosozumab-aqqg contains a boxed warning stating that it may increase the risk of heart attack, stroke, and cardiovascular death and should not be used in patients who have had a heart attack or stroke within the previous year.

    Health professionals should also consider whether the benefits of romosozumab-aqqg outweigh its risks in those with other risk factors for heart disease. The drug should be discontinued in any patient who experiences a heart attack or stroke during treatment.

    In clinical trials, common adverse effects included joint pain, headache, and injection-site reactions.

  • April 10, 2019

    FDA has approved dolutegravir and lamivudine as a complete regimen for treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of the new agent. This is the first two-drug, fixed-dose, complete regimen approved for adults with HIV-1 who have never received treatment.

    The labeling includes a boxed warning cautioning that patients infected with both HIV and hepatitis B should receive additional treatment for their hepatitis B or consider a different drug regimen.

    Patients with both HIV and hepatitis B who take products containing lamivudine, an ingredient in the new combination drug, have developed hepatitis B variants associated with resistance to lamivudine. These patients may have severe liver problems, including liver failure, when they stop taking drugs containing lamivudine. Patients with both HIV and hepatitis B virus who stop using the drug should be closely monitored by their health care provider.

    Efficacy and safety of one tablet of dolutegravir and lamivudine taken daily were demonstrated in two identical, randomized, double-blind, controlled clinical trials in 1,433 HIV-infected adults with no prior antiretroviral treatment history. Results were similar to a drug regimen that included dolutegravir, emtricitabine, and tenofovir in reducing the amount of HIV in the blood. Treatment was considered successful if the patient maintained low levels (<50 copies/mL) of HIV RNA in their blood for at least 48 weeks.  

    The most common adverse reactions were headache, diarrhea, nausea, insomnia, and fatigue.

    As there is a known risk for neural tube defects with dolutegravir, patients are advised to avoid use of the new drug at the time of conception through the first trimester of pregnancy. In May 2018, FDA released a Drug Safety Communication about reported neural tube birth defects in babies born to women treated with dolutegravir.

  • April 9, 2019

    FDA approved testosterone undecanoate, an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland.

    Testosterone undecanoate should not be used to treat men with age-related hypogonadism, in which testosterone levels decline due to aging, even if these men have symptoms that appear to be related to low testosterone. The drug's benefits do not outweigh its risks for that use, according to FDA.

    Efficacy was demonstrated in a 4-month clinical trial involving 166 men with hypogonadism. Study participants initially were given 237 mg of testosterone undecanoate twice per day, and the dose was adjusted downward or upward to a maximum of 396 mg twice per day on the basis of testosterone levels.

    Eighty-seven percent of men treated with the drug achieved an average testosterone level within the normal range, which was the primary study endpoint.

    Testosterone undecanoate contains a boxed warning stating that the drug can cause blood pressure to rise, increasing the risk of heart attack, stroke, and cardiovascular death. Health care providers should consider a patient’s individual heart disease risks and ensure that blood pressure is adequately controlled before prescribing the agent. They should also periodically monitor patient blood pressure during treatment.

    The drug is currently one of two testosterone products that have this boxed warning. FDA is requiring all testosterone product manufacturers to conduct blood pressure postmarketing trials to more clearly address whether these products increase blood pressure.

    Common adverse effects, occurring in more than 2% of patients in the clinical trial, included headache, an increase in red blood cell count, a decrease in HDL-C, high blood pressure, and nausea. An increase in prostate specific antigen (PSA) was also observed. Patients should have their hematocrit, cholesterol, and PSA monitored regularly to check for changes. Those with benign prostate hyperplasia should be monitored for worsening of symptoms.

  • March 27, 2019

    FDA has approved siponimod for treatment of adults with relapsing forms of multiple sclerosis (MS), including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing remitting multiple sclerosis, and clinically isolated syndrome. SPMS is a debilitating form of MS characterized by progressive and irreversible neurological disability. Patients will not require a first dose observation (cardiac monitoring upon initiation) unless they have certain preexisting cardiac conditions.

    Approval was based on groundbreaking data from the Phase III EXPAND study, a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of siponimod versus placebo in people living with SPMS. Patients enrolled in EXPAND were representative of a typical SPMS population. At study initiation, patients had a mean age of 48 years and had been living with MS for approximately 16 years. More than 50% had a median Expanded Disability Status Scale score of 6.0 and relied on a walking aid.

    Siponimod significantly reduced the risk of 3-month confirmed disability progression (CDP), meaningfully delayed the risk of 6-month CDP, and reduced the annualized relapse rate by 55%. Furthermore, EXPAND showed significant favorable outcomes in other relevant measures of MS disease activity, including cognition, MRI disease activity, and brain volume loss.

    The most common adverse reactions (incidence >10%) were headache, hypertension, and transaminase increase.

  • March 27, 2019

    Jazz Pharmaceuticals announced FDA approval of solriamfetol to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). It is the first dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved for this treatment.

    The once-daily drug is approved in doses of 75 mg and 150 mg for patients with narcolepsy and doses of 37.5 mg, 75 mg, and 150 mg for patients with OSA. 

    Approval of solriamfetol was based on data from the TONES Phase III clinical program, which included four randomized placebo-controlled studies that demonstrated the superiority of solriamfetol relative to placebo. The most common adverse reactions reported in both the narcolepsy and OSA study populations were headache, nausea, decreased appetite, and anxiety. Solriamfetol was evaluated in more than 900 adults with excessive daytime sleepiness associated with narcolepsy or OSA and was shown to maintain its effect relative to placebo after 6 months of use.

    In 12 week clinical studies, approximately 68%–74% of people taking solriamfetol at the 75 mg dose and 78%–90% of people taking solriamfetol at the 150 mg dose reported improvement in their overall clinical condition, as assessed by the Patient Global Impression of Change scale.

    Although the exact mechanism of action is unknown, the effects of solriamfetol are thought to be mediated through its activity as a DNRI.

    In a news release, Jazz Pharmaceuticals cautioned that solriamfetol is not indicated to treat the underlying airway obstruction in OSA. Practitioners should ensure that the underlying airway obstruction is treated with continuous positive airway pressure (CPAP) for at least 1 month before initiating solriamfetol for excessive daytime sleepiness in OSA and continued during treatment.